CAMBRIDGE, Mass., Sept 29, 2010 /PRNewswire via COMTEX News Network/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it will now market and sell DELTAZYM(R) GA L-E5, a high performance enzyme for the saccharification of liquefied starch in the fuel ethanol production process. The DELTAZYM(R) GA L-E5 enzyme has demonstrated high ethanol yields at industrial scale using multiple substrates including corn, milo, barley, wheat and cassava.
"Verenium is pleased to be able to enhance our starch processing product offering with this best-in-class glucoamylase enzyme for fuel ethanol production," said Janet Roemer, Verenium's President and Chief Operating Officer. "Customers using both Verenium's Fuelzyme(R) alpha-amylase and DELTAZYM(R) GA L-E5 have reported increased ethanol yields due to demonstrated synergies between the two enzyme products providing fuel ethanol processing plants with superior cost-performance benefits."
Verenium estimates the addressable global market for DELTAZYM(R) GA L-E5 for fuel ethanol production to be approximately $200 million annually.
To learn more about the DELTAZYM(R) GA L-E5 or Fuelzyme(R) enzymes contact Verenium's Customer Relations at email@example.com or 1.800.523.2990.
About DELTAZYM(R) GA L-E5 Glucoamylase
DELTAZYM(R) GA L-E5 is a high activity glucoamylase designed to provide cost benefits and high ethanol yields in fuel ethanol production. DELTAZYM(R) GA L-E5 is used to saccharify liquefied mash from various substrates including corn, milo, barley, wheat and cassava. When used in combination with Verenium's Fuelzyme(R) alpha-amylase, fuel ethanol processing plants have seen superior ethanol yields due to the demonstrated synergies between the substrate that the Fuelzyme(R) product provides and the DELTAZYM(R) GA L-E5 product's main and side activities.
Verenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes. Verenium currently sells enzymes developed using its R&D capabilities to industrial customers globally for use in markets including grain and oilseed processing, biofuels, animal health and nutrition and other specialty industrial processes. Verenium has built a world-class R&D organization renowned for its capabilities in the rapid screening, identification, evolution and bioengineering of novel enzymes that act as catalysts for biochemical reactions. The company harnesses the power of nature and uses its unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance. For more information on Verenium, visit http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's post-closing lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.
Contacts: Kelly Lindenboom Sarah Carmody Vice President, Corporate Communications Manager, Corporate Communications 617-674-5335 617-674-5357 firstname.lastname@example.org email@example.com
SOURCE Verenium Corporation
Copyright (C) 2010 PR Newswire. All rights reserved